URGN
UroGen Pharma Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -10.0% ·
share flow +12.7% ·
net new positions -11.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 20.29K | $750,361 | n/a | n/a |
| Q2 2026 | 76 | +11 | 16.33M | $600.16M | +14 | −3 |
| Q1 2026 | 68 | -2 | 16.64M | $299.41M | +7 | −9 |
| Q4 2025 | 71 | 0 | 16.74M | $392.08M | n/a | n/a |
| Q3 2025 | 18 | -2 | 12.72M | $253.85M | n/a | −2 |
| Q2 2025 | 17 | +1 | 7.27M | $99.60M | +1 | n/a |
| Q1 2025 | 13 | 0 | 4.33M | $47.90M | n/a | n/a |
| Q4 2024 | 13 | +2 | 6.43M | $68.46M | +2 | n/a |
| Q3 2024 | 10 | -2 | 7.92M | $100.53M | n/a | −2 |
| Q2 2024 | 12 | n/a | 7.91M | $132.72M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.58M | +7.3% | $51.50M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 2 | Morgan Stanley ✦ | 2.53M | n/a | $50.44M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 3 | Millennium Management ✦ | 1.47M | +147.2% | $29.30M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 1.07M | n/a | $21.33M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | D. E. Shaw & Co. ✦ | 888.93K | +3140.5% | $17.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 819.45K | +1.5% | $16.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 602.28K | +10.9% | $12.02M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Geode Capital Management ✦ (passive) | 471.23K | +0.1% | $9.40M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Goldman Sachs Group ✦ | 424.92K | n/a | $8.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 386.20K | +103.9% | $7.70M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 356.62K | -1.3% | $7.12M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | The Vanguard Group ✦ (passive) | 303.79K | +19.1% | $6.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 13 | Renaissance Technologies ✦ | 275.10K | +620.2% | $5.49M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 204.19K | -11.8% | $4.07M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 15 | ARK Investment Management ✦ | 126.72K | -23.7% | $2.53M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Wellington Management ✦ | 125.30K | -20.7% | $2.50M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 17 | Fidelity (FMR) ✦ | 73.12K | +2959.2% | $1.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 18 | Marshall Wace ✦ | 18.68K | -9.6% | $372,566 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $11.37M | was 0.0% |
| Point72 Asset Management | $2.31M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 171 holders, 46.40M shares, $801.72M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.20K sh · $80,791
Officer · 1.52K sh · $64,618
Officer · 871 sh · $37,383
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology